Ahn-Gook Pharmaceutical Co. Ltd - Asset Resilience Ratio
Ahn-Gook Pharmaceutical Co. Ltd (001540) has an Asset Resilience Ratio of 3.23% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Ahn-Gook Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Ahn-Gook Pharmaceutical Co. Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Ahn-Gook Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 001540 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩9.80 Billion | 3.23% |
| Total Liquid Assets | ₩9.80 Billion | 3.23% |
Asset Resilience Insights
- Limited Liquidity: Ahn-Gook Pharmaceutical Co. Ltd maintains only 3.23% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ahn-Gook Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Ahn-Gook Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 15.57% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Ahn-Gook Pharmaceutical Co. Ltd (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Ahn-Gook Pharmaceutical Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.82% | ₩23.67 Billion ≈ $16.04 Million |
₩302.54 Billion ≈ $205.02 Million |
-2.13pp |
| 2023-12-31 | 9.96% | ₩23.75 Billion ≈ $16.10 Million |
₩238.60 Billion ≈ $161.69 Million |
-1.54pp |
| 2022-12-31 | 11.50% | ₩25.75 Billion ≈ $17.45 Million |
₩223.91 Billion ≈ $151.74 Million |
-8.96pp |
| 2021-12-31 | 20.46% | ₩43.33 Billion ≈ $29.37 Million |
₩211.80 Billion ≈ $143.53 Million |
-2.86pp |
| 2020-12-31 | 23.32% | ₩47.03 Billion ≈ $31.87 Million |
₩201.70 Billion ≈ $136.69 Million |
+3.30pp |
| 2019-12-31 | 20.02% | ₩43.64 Billion ≈ $29.58 Million |
₩217.96 Billion ≈ $147.71 Million |
+3.86pp |
| 2018-12-31 | 16.16% | ₩34.41 Billion ≈ $23.32 Million |
₩212.92 Billion ≈ $144.30 Million |
-1.08pp |
| 2017-12-31 | 17.24% | ₩35.87 Billion ≈ $24.31 Million |
₩208.07 Billion ≈ $141.00 Million |
+1.43pp |
| 2016-12-31 | 15.81% | ₩31.02 Billion ≈ $21.02 Million |
₩196.27 Billion ≈ $133.01 Million |
+5.41pp |
| 2015-12-31 | 10.40% | ₩20.57 Billion ≈ $13.94 Million |
₩197.85 Billion ≈ $134.08 Million |
-0.71pp |
| 2014-12-31 | 11.11% | ₩19.90 Billion ≈ $13.49 Million |
₩179.07 Billion ≈ $121.35 Million |
-5.27pp |
| 2013-12-31 | 16.38% | ₩26.74 Billion ≈ $18.12 Million |
₩163.24 Billion ≈ $110.63 Million |
-3.49pp |
| 2012-12-31 | 19.88% | ₩33.36 Billion ≈ $22.61 Million |
₩167.83 Billion ≈ $113.74 Million |
-2.10pp |
| 2011-12-31 | 21.98% | ₩36.01 Billion ≈ $24.40 Million |
₩163.85 Billion ≈ $111.04 Million |
-- |
About Ahn-Gook Pharmaceutical Co. Ltd
Ahn-Gook Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products. The company's pharmaceutical products include Cinatura and Revo Tension. The company was founded in 1959 and is headquartered in Seoul, South Korea.